Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8049817 | 0.89 | RIPK2 (0.50) | RIPK2RAB9ALMNASMN1; SMN2MAPK14 | |
| SCHEMBL8047290 | 0.84 | RIPK2 (0.50) | RIPK2RAB9ALMNASMN1; SMN2MAPK14 | |
| SCHEMBL8043562 | 0.84 | RIPK2 (0.50) | RIPK2RAB9ALMNASMN1; SMN2MAPK14 | |
| SCHEMBL8049319 | 0.84 | RIPK2 (0.50) | RIPK2RAB9ALMNASMN1; SMN2MAPK14 | |
| SCHEMBL8043800 | 0.84 | RIPK2 (0.50) | RIPK2RAB9ALMNASMN1; SMN2MAPK14 | |
| SCHEMBL8045963 | 0.83 | MAPK14 (0.58) | RIPK2RAB9ALMNASMN1; SMN2MAPK14 | |
| SCHEMBL8041196 | 0.82 | RIPK2 (0.51) | RIPK2RAB9ALMNASMN1; SMN2MAPK14 | |
| SCHEMBL8044057 | 0.81 | RIPK2 (0.50) | RIPK2RAB9ALMNASMN1; SMN2MAPK14 | |
| SCHEMBL8040355 | 0.81 | RIPK2 (0.50) | RIPK2RAB9ALMNASMN1; SMN2MAPK14 | |
| SCHEMBL3830233 | 0.77 | RIPK2 (0.71) | RIPK2RAB9ALMNASMN1; SMN2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648085-B2 | 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-8648085-B2 | 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-20110015193-A1 | 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MUDULATORS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015193-A1 | 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MUDULATORS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| WO-2009068617-A1 | 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS FOR THE TEATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015193-A1 | 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MUDULATORS FOR THE TREATMENT OF CNS DISORDERS | PDE9A, PDE7A, PDE1C | RIPK2 4088/4885RAB9A 87/4885LMNA 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.